SLC5A2 and type 2 diabetes mellitus: Currently, sodium–glucose linked transporter 2 (SGLT2) inhibitors are included in the contemporary therapy of different phenotypes of HF regardless of T2DM presentation, while until now, the underlying mechanisms by which these agents are exerted, and their ability to improve clinical outcomes and hemodynamics, are not deeply understood.